He YG, Wang Z, Li J, Xi W, Zhao CY, Huang XB, Zheng L. Pathologic complete response to conversion therapy in hepatocellular carcinoma using patient-derived organoids: A case report. World J Gastrointest Oncol 2024; 16(11): 4506-4513 [PMID: 39554753 DOI: 10.4251/wjgo.v16.i11.4506]
Corresponding Author of This Article
Lu Zheng, Doctor, MD, PhD, Associate Specialist, Deputy Director, Doctor, Professor, Department of Hepatobiliary, The Second Affiliated Hospital of Army Medical University, No. 183 Xinqiao High Street, Shapingba District, Chongqing 400037, China. zhenglu@tmmu.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4506-4513 Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4506
Pathologic complete response to conversion therapy in hepatocellular carcinoma using patient-derived organoids: A case report
Yong-Gang He, Zheng Wang, Jing Li, Wang Xi, Chong-Yu Zhao, Xiao-Bing Huang, Lu Zheng
Yong-Gang He, Zheng Wang, Jing Li, Wang Xi, Chong-Yu Zhao, Xiao-Bing Huang, Lu Zheng, Department of Hepatobiliary, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
Co-first authors: Yong-Gang He and Zheng Wang.
Author contributions: He YG, Li J and Wang Z were responsible for writing the first draft; Xi W and Zhao CY participated in data acquisition and investigation. Supervision was performed by Huang XB and Zheng L. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. All the authors contributed to the study conception and design. He YG and Wang Z contributed equally to this work as co-first authors.
Supported byChongqing Natural Science Foundation Project, No. CSTB2022NSCQ-MSX0172; and Incubation Project for Talented Young People, No. 2022YQB031.
Informed consent statement: The patient provided the written informed consent to participate in this study. Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lu Zheng, Doctor, MD, PhD, Associate Specialist, Deputy Director, Doctor, Professor, Department of Hepatobiliary, The Second Affiliated Hospital of Army Medical University, No. 183 Xinqiao High Street, Shapingba District, Chongqing 400037, China. zhenglu@tmmu.edu.cn
Received: February 15, 2024 Revised: September 12, 2024 Accepted: September 20, 2024 Published online: November 15, 2024 Processing time: 252 Days and 19.6 Hours
Abstract
BACKGROUND
For primary liver cancer, the key to conversion therapy depends on the effectiveness of drug treatment. Patient-derived tumor organoids have been demonstrated to improve the efficacy of conversion therapy by identifying individual-targeted effective drugs, but their clinical effects in liver cancer remain unknown.
CASE SUMMARY
We described a patient with hepatocellular carcinoma (HCC) who achieved pathologic complete response (pCR) to conversion therapy guided by the patient-derived organoid (PDO) drug sensitivity testing. Despite insufficiency of the remaining liver volume after hepatectomy, the patient obtained tumor reduction after treatment with the PDO-sensitive drugs and successfully underwent radical surgical resection. Postoperatively, pCR was observed.
CONCLUSION
PDOs contributes to screening sensitive drugs for HCC patients to realize the personalized treatment and improve the conversion therapy efficacy.
Core Tip: Patient-derived tumor organoids have been demonstrated to improve the efficacy of conversion therapy by identifying individual-targeted effective drugs. Here we described a patient with hepatocellular carcinoma (HCC) who achieved pathologic complete response to conversion therapy guided by the patient-derived organoid (PDO) drug sensitivity testing. This typical case suggests that PDO-based drug sensitivity testing contributes to screening sensitive drugs for HCC patients to realize the personalized treatment and to improve the efficacy of conversion therapy, which may change the previous experiential therapy and serve as a novel treatment mode in liver cancer.
